

# Navneet S Majhail

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/996934/publications.pdf>

Version: 2024-02-01

133  
papers

4,343  
citations

101535  
36  
h-index

118840  
62  
g-index

135  
all docs

135  
docs citations

135  
times ranked

4753  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 335-343.	1.3	5
2	Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 671-673.	2.4	2
3	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 310-320.	1.2	11
4	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1031-1033.	2.4	1
5	Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2679-2685.	1.3	3
6	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12
7	Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 222-229.	1.2	27
8	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	1.4	34
9	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	1.2	45
10	Secular trends of Blood stream infections in allogeneic hematopoietic cell transplant recipients 72 hours prior to death. <i>Transplant Infectious Disease</i> , 2021, 23, e13631.	1.7	1
11	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. <i>JCI Insight</i> , 2021, 6, .	5.0	12
12	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	1.2	3
13	Image-guided volumetric-modulated arc therapy of total body irradiation: An efficient workflow from simulation to delivery. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 169-177.	1.9	13
14	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1344-1352.	1.3	7
15	Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	0
16	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	1.4	27
17	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2899-2899.	1.4	1
18	Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors. <i>Blood</i> , 2021, 138, 4123-4123.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Community Health Status and Long-Term Outcomes in 1-Year Survivors of Autologous and Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 422-422.	1.4	0
20	Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans. <i>Blood</i> , 2021, 138, 431-431.	1.4	0
21	Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 275-280.	2.5	19
22	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 262-271.	2.0	17
23	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 160-165.	0.9	8
24	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	4.1	28
25	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 32-39.	0.9	7
26	Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 70-77.	0.4	10
27	Severity of acute gastrointestinal graft-versus-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13217.	1.7	10
28	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 906-917.	2.4	33
29	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1505-1510.	2.0	11
30	Not So Young at Heart. <i>JACC: CardioOncology</i> , 2020, 2, 472-474.	4.0	0
31	Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 14, 318-326.	0.9	7
32	To D or not to D: vitamin D in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2060-2070.	2.4	6
33	Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints. <i>Bone Marrow Transplantation</i> , 2020, 55, 1533-1539.	2.4	4
34	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <i>American Journal of Hematology</i> , 2020, 95, 672-690.	4.1	22
35	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
36	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17

#	ARTICLE	IF	CITATIONS
37	Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2335-2345.	2.0	28
38	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
39	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 38-39.	1.4	2
40	Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
41	Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
42	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. <i>Blood</i> , 2020, 136, 21-21.	1.4	0
43	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e344-e351.	2.0	59
44	Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population. <i>Leukemia and Lymphoma</i> , 2019, 60, 3544-3551.	1.3	4
45	Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2522-2526.	2.0	4
46	Penicillin allergy skin testing as an antibiotic stewardship intervention reduces alternative antibiotic exposures in hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13175.	1.7	12
47	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 439-445.	4.1	12
48	Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1443-1452.	2.4	21
49	High-dose chemotherapy and autologous transplantation for testicular germ cell tumors. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e47.	0.9	2
50	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2086-2090.	2.0	42
51	Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma. <i>Transplant Infectious Disease</i> , 2019, 21, e13114.	1.7	19
52	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 845-854.	2.0	69
53	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1553-1561.	2.4	6
54	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2732-2737.	5.2	9

#	ARTICLE	IF	CITATIONS
55	Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 664-672.	2.0	3
56	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. <i>Haematologica</i> , 2019, 104, 1084-1092.	3.5	46
57	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2019, 54, 1281-1286.	2.4	24
58	Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 775-781.	2.4	14
59	Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 562-569.	2.0	16
60	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e155-e162.	2.0	56
61	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
62	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1107-1115.	2.0	9
63	Twitter Use in the Hematopoietic Cell Transplantation Community. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 53-58.	2.3	12
64	Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1546-1553.	2.0	40
65	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1029-1034.	2.0	19
66	Community Risk Score for Evaluating Health Care Disparities in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 877-879.	2.0	9
67	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
68	Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1278-1287.	2.4	25
69	Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 4-12.	2.0	6
70	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
71	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 1195-1201.	1.3	11
72	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e95-e102.	0.4	6

#	ARTICLE	IF	CITATIONS
73	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	4.1	44
74	Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. <i>Journal of Clinical Apheresis</i> , 2018, 33, 303-309.	1.3	6
75	Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e11-e19.	2.0	21
76	Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 576-580.	2.3	5
77	Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2145-2151.	2.0	14
78	Infectious complications in multiple myeloma (MM) patients receiving autologous hematopoietic cell transplantation (AutoHCT) in the contemporary era.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20003-e20003.	1.6	0
79	Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 4835-4835.	1.4	0
80	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2075-2075.	1.4	0
81	Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1899-1899.	1.4	3
82	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , 2018, 132, 371-371.	1.4	0
83	Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) As a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes. <i>Blood</i> , 2018, 132, 3600-3600.	1.4	0
84	Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400Â%cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 776-781.	2.0	3
85	Race colors transplantation utilization for multiple myeloma. <i>Cancer</i> , 2017, 123, 3005-3006.	4.1	0
86	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
87	Impact of social media for the hematologist/oncologist. <i>Seminars in Hematology</i> , 2017, 54, 193-197.	3.4	11
88	Long-term complications after hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 220-227.	0.9	116
89	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 6-9.	2.0	49
90	National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 717-725.	2.0	40

#	ARTICLE	IF	CITATIONS
91	Patient-centered care coordination in hematopoietic cell transplantation. Blood Advances, 2017, 1, 1617-1627.	5.2	28
92	Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation: Risk Stratification and Outcomes. Open Forum Infectious Diseases, 2017, 4, S727-S728.	0.9	0
93	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. Blood, 2017, 130, 847-847.	1.4	8
94	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
95	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Timesâ€“Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1588-1595.	2.0	9
96	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biology of Blood and Marrow Transplantation, 2016, 22, 1915-1925.	2.0	130
97	Supportive care in alternative donor transplantation. Seminars in Hematology, 2016, 53, 129-135.	3.4	3
98	Association of Socioeconomic Status with Outcomes ofÂ“Autologous Hematopoietic Cell Transplantation for MultipleÂ“Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 1141-1144.	2.0	9
99	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2016, 128, 4666-4666.	1.4	0
100	Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. Current Hematologic Malignancy Reports, 2015, 10, 405-412.	2.3	46
101	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. Biology of Blood and Marrow Transplantation, 2015, 21, 1308-1314.	2.0	45
102	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1155-1166.	2.0	104
103	Guidelines for Defining and Implementing Standard Episode of Care for Hematopoietic Stem Cell Transplantation within the Context of Clinical Trials. Biology of Blood and Marrow Transplantation, 2015, 21, 583-588.	2.0	18
104	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
105	Conditioning regimens for refractory acute myeloid leukaemia. Lancet Haematology,the, 2015, 2, e354-e355.	4.6	0
106	Optimizing Quality and Efficiency of Healthcare Delivery in Hematopoietic Cell Transplantation. Current Hematologic Malignancy Reports, 2015, 10, 199-204.	2.3	11
107	Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era. Biology of Blood and Marrow Transplantation, 2015, 21, 142-150.	2.0	66
108	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 151-158.	2.0	49



#	ARTICLE	IF	CITATIONS
109	Association of Socioeconomic Status (SES) with Outcomes of Autologous Hematopoietic Cell Transplantation (ASCT) for Lymphoma. <i>Blood</i> , 2015, 126, 4494-4494.	1.4	0
110	Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1819-1827.	2.0	43
111	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
112	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1116-1123.	2.0	104
113	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2437-2449.	1.6	223
114	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 348-371.	2.0	324
115	Allogeneic Transplant Physician and Center Capacity in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 956-961.	2.0	43
116	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	1.4	319
117	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. <i>Haematologica</i> , 2011, 96, 1528-1535.	3.5	48
118	To cry or not to cry: physicians and emotions at the bedside. <i>Minnesota Medicine</i> , 2011, 94, 40-2.	0.1	1
119	Access to hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 3469-3476.	4.1	124
120	The National Marrow Donor Program's Symposium on Patient Advocacy in Cellular Transplantation Therapy: Addressing Barriers to Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 147-156.	2.0	15
121	Access to Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1070-1075.	2.0	85
122	Late complications in blood and marrow transplant survivors. <i>Minnesota Medicine</i> , 2010, 93, 45-9.	0.1	15
123	The Homecoming. <i>Journal of Clinical Oncology</i> , 2009, 27, 5857-5858.	1.6	1
124	Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 129-139.	2.5	59
125	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1543-1554.	2.0	135
126	Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 282-289.	2.0	119



#	ARTICLE	IF	CITATIONS
127	Late Effects in Survivors of Hodgkin and Non-Hodgkin Lymphoma Treated with Autologous Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study. Biology of Blood and Marrow Transplantation, 2007, 13, 1153-1159.	2.0	99
128	Diffuse Alveolar Hemorrhage and Infection-Associated Alveolar Hemorrhage following Hematopoietic Stem Cell Transplantation: Related and High-Risk Clinical Syndromes. Biology of Blood and Marrow Transplantation, 2006, 12, 1038-1046.	2.0	130
129	Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 1065-1072.	2.0	171
130	Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood, 2006, 107, 3804-3807.	1.4	103
131	Adjuvant Subcutaneous Interleukin-2 in Patients with Resected Renal Cell Carcinoma: A Pilot Study. Clinical Genitourinary Cancer, 2006, 5, 50-56.	1.9	9
132	Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas. Psychophysiology, 2005, 4, 252-9.	1.1	4
133	Acute leukemia with a very high leukocyte count: confronting a medical emergency.. Cleveland Clinic Journal of Medicine, 2004, 71, 633-637.	1.3	59